Clinical Trial Update: Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update showing biomarker effects of ALZ-801 in APOE4 carriers with early Alzheimer's disease. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ALZ-801

Snippet

Sponsor: Alzheon Inc. | Conditions: Early Alzheimer's Disease | Phase 2 | Status: COMPLETED